CD38 and neoplasm: These results raise the possibility that daratumumab and other CD38-specific Abs might actually promote an immunosuppressive tumor microenvironment, i.e., by promoting CD38-mediated hydrolysis of NAD+, a crucial step in the pathway that generates adenosine from NAD+ [3,43].